Results 31 to 40 of about 32,892 (194)

Clinical evaluation of nebulized verapamil in out‐patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease

open access: yesThe Clinical Respiratory Journal, 2022
Objective Chronic obstructive pulmonary disease (COPD) is associated with many health complications, including pulmonary hypertension (PH). Although oral calcium channel blockers have shown promising results in managing COPD‐induced PH, significant ...
Fanak Fahimi   +6 more
doaj   +1 more source

Verapamil chronicles: advances from cardiovascular to pancreatic β-cell protection

open access: yesFrontiers in Pharmacology, 2023
Verapamil is a well-known drug used for treating angina and hypertension. Emerging data from current clinical trials suggest that this calcium channel blocker has a potential benefit for pancreatic β-cells through the elevation and sustenance of C ...
Hossein Arefanian   +7 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson   +8 more
wiley   +1 more source

Verapamil Attenuates the Severity of Tendinopathy by Mitigating Mitochondrial Dysfunction through the Activation of the Nrf2/HO-1 Pathway

open access: yesBiomedicines
Tendinopathy is a prevalent condition in orthopedics patients, exerting a profound impact on tendon functionality. However, its underlying mechanism remains elusive and the efficacy of pharmacological interventions continues to be suboptimal.
Zengguang Wang   +6 more
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet   +11 more
wiley   +1 more source

Verapamil Alleviates Myocardial Ischemia/Reperfusion Injury by Attenuating Oxidative Stress via Activation of SIRT1

open access: yesFrontiers in Pharmacology, 2022
Myocardial ischemia/reperfusion (I/R) injury is a potential complication of ischemic heart disease after recanalization. One of the primary reasons for I/R injury is the excessive accumulation of reactive oxygen species (ROS) in cardiomyocytes. Verapamil,
Mi Bao   +15 more
doaj   +1 more source

The Synthesis Use of a Difluorinated Amino‐Benzo‐Cinnoline Dyes (ABCDyes) Enables Fine Tuning of Emission Through Double SNAr Late‐Stage Functionalization

open access: yesEuropean Journal of Organic Chemistry, EarlyView.
An efficient synthesis of difluorinated amino‐benzo‐cinnoline dyes (ABCDyes) is reported. Their use for the late‐stage introduction of internal dinucleophilic species through a double SNAr reaction enables straightforward access to previously unexplored ABCDye analogs displaying tunable emission ranging from green to red.
Mélina Fabe   +3 more
wiley   +1 more source

Therapeutic‐dose verapamil‐induced cardiogenic shock in an older patient: a case report

open access: yesJournal of Pharmacy Practice and Research, EarlyView.
Abstract Background Calcium channel blocker (CCB) toxicity most commonly follows deliberate overdose. However, severe toxicity at therapeutic doses may occur in susceptible individuals. Severe CCB toxicity often presents with clinical features of bradycardia, hypotension, hyperglycaemia, and lactic acidosis.
Christopher Thuring   +3 more
wiley   +1 more source

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort

open access: yesMovement Disorders, EarlyView.
Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard   +9 more
wiley   +1 more source

Verapamil Inhibits Aspergillus Biofilm, but Antagonizes Voriconazole

open access: yesJournal of Fungi, 2017
The paucity of effective antifungals against Aspergillus and increasing resistance, the recognition of the importance of Aspergillus biofilm in several clinical settings, and reports of verapamil—a calcium channel blocker—efficacy against Candida biofilm
Hasan Nazik   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy